Outcomes after SCB in the published literature
| Publication . | No. of patients . | Indication for SCB∗ . | Median CD34+ 106/kg at SCB . | Best response† . | Median time to best response (range), d . | Median OS . | Active infection at SCB‡ . | Predictors of treatment failure after SCB on univariable or multivariable analysis . | Ref . |
|---|---|---|---|---|---|---|---|---|---|
| Al-Ramahi et al, 2023 | 51 | PGF | 4.8 | CR, 37/51 (72.5%), PR: 5/51 (9.8%) | 27.5 d (22-41) | 6 mo | 6/51 (12%) viral infections, 9/51 (18%) bacterial infections, 2/51 (4%) fungal infections | Poor Karnofsky performance status, prior acute GVHD, active hospitalization, bacterial infection at SCB | 12 |
| Gaffet et al, 2023 | 55 | PGF | 5.9 | 12-mo CR, 23/49 (47%), 12-mo PR, 5/49 (10%) | 19/23 (39%) attained CR at 30 d post SCB | 2-y OS 60% | 0/51 (0%) | Lower ANC at the time of SCB | 10 |
| Cuadrado et al, 2020 | 62 | PGF | 3.2 | CR, 39/62 (63%), PR, 8/62 (13%) | ANC, 29 d (6-1182), Plts, 18 d (5-600), Hb, 25 d (6-511) | All, 5.4 y, if in CR: 5-y OS 74% | 24/62 (39%) | Donor or recipient CMV seropositive, donor/recipient sex mismatch, active infection at time of boost | 7 |
| Mainardi et al, 2017 | 50 | PGF | 3.2 | CR, 18/50 (36.5%), PR, 21/50 (42.3%) | ANC, 64% attained response at 56 d post SCB, Plt: transfusion indep attained in 58.8% at 56 d post SCB, Hb: transfusion indep in 47% at 56 d post SCB | 5-y OS 38% | Not available | Donor age >40 at HCT | 13 |
| Publication . | No. of patients . | Indication for SCB∗ . | Median CD34+ 106/kg at SCB . | Best response† . | Median time to best response (range), d . | Median OS . | Active infection at SCB‡ . | Predictors of treatment failure after SCB on univariable or multivariable analysis . | Ref . |
|---|---|---|---|---|---|---|---|---|---|
| Al-Ramahi et al, 2023 | 51 | PGF | 4.8 | CR, 37/51 (72.5%), PR: 5/51 (9.8%) | 27.5 d (22-41) | 6 mo | 6/51 (12%) viral infections, 9/51 (18%) bacterial infections, 2/51 (4%) fungal infections | Poor Karnofsky performance status, prior acute GVHD, active hospitalization, bacterial infection at SCB | 12 |
| Gaffet et al, 2023 | 55 | PGF | 5.9 | 12-mo CR, 23/49 (47%), 12-mo PR, 5/49 (10%) | 19/23 (39%) attained CR at 30 d post SCB | 2-y OS 60% | 0/51 (0%) | Lower ANC at the time of SCB | 10 |
| Cuadrado et al, 2020 | 62 | PGF | 3.2 | CR, 39/62 (63%), PR, 8/62 (13%) | ANC, 29 d (6-1182), Plts, 18 d (5-600), Hb, 25 d (6-511) | All, 5.4 y, if in CR: 5-y OS 74% | 24/62 (39%) | Donor or recipient CMV seropositive, donor/recipient sex mismatch, active infection at time of boost | 7 |
| Mainardi et al, 2017 | 50 | PGF | 3.2 | CR, 18/50 (36.5%), PR, 21/50 (42.3%) | ANC, 64% attained response at 56 d post SCB, Plt: transfusion indep attained in 58.8% at 56 d post SCB, Hb: transfusion indep in 47% at 56 d post SCB | 5-y OS 38% | Not available | Donor age >40 at HCT | 13 |
CMV, cytomegalovirus; indep, independence; Plt, platelet; Ref, reference.
∗†‡Definitions of poor graft function, criteria for response, and definition of active infection used in the individual studies are presented in supplemental Table 8.